Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function.
Carter J, Huang HQ, Armer J, Carlson JW, Lockwood S, Nolte S, Kauderer J, Hutson A, Walker JL, Fleury AC, Bonebrake A, Soper JT, Mathews C, Zivanovic O, Richards WE, Tan A, Alberts DS, Barakat RR, Wenzel LB. Carter J, et al. Among authors: bonebrake a. Gynecol Oncol. 2021 Jan;160(1):244-251. doi: 10.1016/j.ygyno.2020.10.023. Epub 2020 Oct 24. Gynecol Oncol. 2021. PMID: 33109392 Free PMC article. Review.
GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE).
Carter J, Huang HQ, Armer J, Carlson JW, Lockwood S, Nolte S, Stewart BR, Kauderer J, Hutson A, Walker JL, Fleury AC, Bonebrake A, Soper JT, Mathews C, Zivanovic O, Richards WE, Tan A, Alberts DS, Barakat RR, Wenzel L. Carter J, et al. Among authors: bonebrake a. Gynecol Oncol. 2019 Dec;155(3):452-460. doi: 10.1016/j.ygyno.2019.09.027. Epub 2019 Oct 31. Gynecol Oncol. 2019. PMID: 31679787 Free PMC article.
GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients.
Carlson JW, Kauderer J, Hutson A, Carter J, Armer J, Lockwood S, Nolte S, Stewart BR, Wenzel L, Walker J, Fleury A, Bonebrake A, Soper J, Mathews C, Zivanovic O, Richards WE, Tan A, Alberts DS, Barakat RR. Carlson JW, et al. Among authors: bonebrake a. Gynecol Oncol. 2020 Feb;156(2):467-474. doi: 10.1016/j.ygyno.2019.10.009. Epub 2019 Dec 16. Gynecol Oncol. 2020. PMID: 31837831 Free PMC article.
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
Monk BJ, Kauderer JT, Moxley KM, Bonebrake AJ, Dewdney SB, Secord AA, Ueland FR, Johnston CM, Aghajanian C. Monk BJ, et al. Among authors: bonebrake aj. Gynecol Oncol. 2018 Dec;151(3):422-427. doi: 10.1016/j.ygyno.2018.10.001. Epub 2018 Oct 8. Gynecol Oncol. 2018. PMID: 30309721 Free PMC article. Clinical Trial.
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
Tew WP, Sill MW, Walker JL, Secord AA, Bonebrake AJ, Schilder JM, Stuckey A, Rice L, Tewari KS, Aghajanian CA. Tew WP, et al. Among authors: bonebrake aj. Gynecol Oncol. 2018 Nov;151(2):257-263. doi: 10.1016/j.ygyno.2018.08.027. Epub 2018 Aug 31. Gynecol Oncol. 2018. PMID: 30177462 Free PMC article. Clinical Trial.
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
Farley JH, Brady WE, O'Malley D, Fujiwara K, Yonemori K, Bonebrake A, Secord AA, Stephan JM, Walker JL, Nam JH, Birrer MJ, Gershenson DM. Farley JH, et al. Among authors: bonebrake a. Gynecol Oncol. 2022 Dec;167(3):423-428. doi: 10.1016/j.ygyno.2022.10.006. Epub 2022 Oct 14. Gynecol Oncol. 2022. PMID: 36244829 Free PMC article. Clinical Trial.
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.
Pitiyarachchi O, Friedlander M, Java JJ, Chan JK, Armstrong DK, Markman M, Herzog TJ, Monk BJ, Backes F, Secord AA, Bonebrake A, Rose PG, Tewari KS, Lentz SS, Geller MA, Copeland LJ, Mannel RS. Pitiyarachchi O, et al. Among authors: bonebrake a. Gynecol Oncol. 2022 Sep;166(3):410-416. doi: 10.1016/j.ygyno.2022.07.004. Epub 2022 Jul 11. Gynecol Oncol. 2022. PMID: 35835612 Free PMC article.
26 results